KRAS Inhibitors Market Summary
The KRAS Inhibitors market is on the cusp of a transformative decade, driven by unprecedented scientific breakthroughs, regulatory milestones, and a rapidly expanding pipeline of targeted oncology therapies. Valued at approximately USD 526 million across the Seven Major Markets (7MM) in 2025, the market is projected to reach USD 7,847 million by 2034, representing one of the most dynamic growth trajectories in the modern oncology landscape.
The KRAS Inhibitors market research indicates that this market is projected to grow at a compound annual growth rate (CAGR) of approximately 35% through 2034 across leading geographies, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. This remarkable CAGR reflects not only the increasing clinical recognition of KRAS mutations as critical oncogenic drivers but also the accelerating pace of drug development targeting these historically “undruggable” proteins.
Among the 7MM, the United States captured the highest KRAS inhibitors market share in 2024, accounting for nearly 70% of total market revenue. This dominance is attributed to the early regulatory approvals of key therapies, a well-established oncology reimbursement framework, high molecular testing adoption rates, and a concentrated presence of leading biopharmaceutical innovators.
Within the EU4 and the United Kingdom, Germany emerged as the country with the highest market size in 2024, supported by robust healthcare infrastructure and strong oncology drug uptake. Spain, on the other hand, recorded the lowest market size among EU4 and UK countries, reflecting variations in reimbursement policies and testing penetration rates.
KRAS Inhibitors Epidemiology
The KRAS Inhibitors market insight is fundamentally anchored in a patient-based epidemiological model that provides a granular understanding of disease burden across geographies and tumor types. The epidemiology chapter covers historical and forecasted data from 2020 to 2034 across the 7MM, segmented by:
- Total incident cases of Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Cancer, and Low-Grade Serous Ovarian Cancer (LGSOC)
- Total KRAS incident cases across each tumor type
- Total KRAS variant-specific cases (including G12C, G12D, and others) across the 7MM
Key Findings from KRAS Inhibitors Epidemiological Analyses and Forecast:
- The total KRAS-mutated cases across the 7MM exceeded approximately 509,700 cases in 2024 and are projected to increase steadily throughout the forecast period.
- Among the selected cancer types, the highest KRAS mutant case burden is found in CRC, followed by pancreatic cancer, NSCLC, and LGSOC. In the United States alone, there were approximately 66,000 cases of KRAS mutant colorectal cancer in 2024.
- The most frequent KRAS variant in NSCLC is G12C, present in approximately 37% of NSCLC cases in the United States.
- The most common KRAS variation in CRC, pancreatic cancer, and LGSOC is G12D, with highest rates of approximately 30%, 42%, and 42%, respectively.
- In Japan, the contribution of KRAS mutations is comparatively lower than in Western countries such as the United States and Europe, reflecting distinct molecular epidemiology patterns.
KRAS Inhibitors Market Recent Developments and Breakthroughs
The KRAS Inhibitors market trends are being shaped by a series of high-impact regulatory decisions and late-stage clinical data emerging across multiple tumor types:
- May 2025: Verastem Oncology announced FDA approval of AVMAPKI + FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) for adult patients with KRAS-mutated recurrent LGSOC who received prior systemic therapy — marking the first and only FDA-approved medicine for this disease, granted under accelerated approval based on tumor response rate and duration of response (DoR).
- April 2025: Bristol Myers Squibb (BMS) announced anticipated Phase III data readouts for KRYSTAL-10 by 2026 (2L CRC), KRYSTAL-7 in 2028 (1L NSCLC, PD-L1 ≥50%), and KRYSTAL-4 in 2029 (1L NSCLC).
- March 2025: Verastem Oncology announced plans to launch avutometinib in the first half of 2025 and submit for NCCN Guideline inclusion upon FDA approval, potentially enabling access for patients with KRAS wild-type LGSOC.
- Q1 2025: According to BMS presentations, KRAZATI (KRYSTAL-17) early-stage data for 1L NSCLC (TPS <50%) are anticipated in 2025.
- January 2025: Elicio Therapeutics announced plans to submit a Biologics License Application (BLA) contingent upon Phase III trial results, following FDA feedback from an End of Phase I Type B meeting.
KRAS Inhibitor Marketed Drugs
LUMAKRAS/LUMYKRAS (sotorasib) – Amgen
LUMAKRAS is an inhibitor of the RAS GTPase family approved for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. It received FDA accelerated approval in May 2021, conditional marketing authorization in the European Union, and Japanese approval in January 2022. The drug also carries Breakthrough Therapy Designation (BTD) from the US FDA.
- In December 2024, Amgen confirmed that LUMAKRAS holds multiple patents in the US and Europe, ensuring market exclusivity through 2040.
- In December 2023, the FDA issued a Complete Response Letter for LUMAKRAS’s supplemental NDA for full approval based on the CodeBreaK 200 trial, with a confirmatory study postmarketing requirement to be completed by February 2028.
KRAZATI (adagrasib) – Bristol Myers Squibb (Mirati Therapeutics)
KRAZATI is an oral targeted therapy for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. It received FDA approval and launched commercially in the US in December 2022. In January 2024, the European Commission granted conditional marketing authorization for KRAZATI in KRASG12C-mutated advanced NSCLC.
- Confirmatory results from the KRYSTAL-12 trial in 2L+ NSCLC are expected in 2025 or 2026.
- KRYSTAL-17 early-stage data for 1L NSCLC (TPS <50%) are anticipated in 2025.
KRAS Inhibitor Emerging Drugs
Olomorasib (LY3537982) – Eli Lilly and Company
Olomorasib is an investigational, oral, potent, and highly selective second-generation KRAS G12C inhibitor designed for high predicted target occupancy as monotherapy or in combination. It is currently in Phase III development across three clinical trials focused on KRAS G12C-mutant advanced NSCLC and other solid tumors. In June 2024, Eli Lilly presented updated Phase I/II results at the 2024 ASCO Annual Meeting.
MK-1084 – Merck, Taiho, and Astex Pharmaceuticals
MK-1084 is an investigational oral, selective KRAS G12C inhibitor being developed in combination with KEYTRUDA (pembrolizumab) through a collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical.
- In May 2025, Merck anticipated a data readout at ASCO 2025.
- In February 2025, the anticipated US patent expiration for MK-1084 was confirmed as 2040.
- Phase III data readout is anticipated by 2028 and beyond.
Leading KRAS Inhibitor Companies
The competitive landscape of the KRAS inhibitors space includes a diverse and growing roster of global pharmaceutical and biotechnology companies. The leading organizations developing potential therapies include: Roche, Chugai, Genentech, Revolution Medicines, Eli Lilly and Company, Merck, Taiho, Astex Pharmaceuticals, Cardiff Oncology, Elicio Therapeutics, Jiangsu Hengrui Pharmaceuticals, Genfleet Therapeutics, Innovent, Jacobio Pharma, Tyligand Pharmaceuticals (Suzhou), Silexion Therapeutics, Catalent, Astellas Pharma, Incyte, Pfizer, Bayer, Kumquat Biosciences, Quanta Therapeutics, Amgen, Bristol Myers Squibb (Mirati Therapeutics), and Verastem Oncology.
Conclusion
The KRAS inhibitors landscape is undergoing a profound transformation. From the first approvals of sotorasib and adagrasib to the emerging wave of next-generation inhibitors and combination strategies, the market reflects decades of scientific persistence finally yielding clinical and commercial results. With rising patient identification through expanded molecular testing, broadening indications across tumor types, and a pipeline encompassing both G12C-specific and pan-KRAS approaches, the coming decade promises to redefine the standard of care for some of the most difficult-to-treat malignancies. Continued investment in biomarker-driven research, regulatory collaboration, and equitable global access will be essential to fully realizing the potential of this rapidly evolving therapeutic class.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
